Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00957918 · ClinicalTrials.gov registry record · Phase 1
Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy
A Phase 1 study, sponsored by Neuraltus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT00957918 is a Phase 1 study that has completed, run by Neuraltus Pharmaceuticals. The registered enrollment target is 65 participants.
The verdict
NCT00957918, a Phase 1 study, has completed, sponsored by Neuraltus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The study is designed to answer the question: will nicotine at doses that do not cause serious side effects, show feasibility in treatment of levodopa-induced dyskinesia in patients with Parkinson's disease?
Interventions
- OTHER placebo comparator
- DRUG nicotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00957918
The ClinicalTrials.gov registry entry for NCT00957918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuraltus Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo comparator is the first listed.
NCT00957918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00957918 about?
NCT00957918 is a clinical study titled "Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy". The study is designed to answer the question: will nicotine at doses that do not cause serious side effects, show feasibility in treatment of levodopa-induced dyskinesia in patients with Parkinson's disease?
What is the current status of trial NCT00957918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2009-10. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00957918?
The interventions under investigation include: placebo comparator (OTHER), nicotine (DRUG).
Who is sponsoring clinical trial NCT00957918?
This trial is sponsored by Neuraltus Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.